The largest real-world human analysis of the use of a combination of ivermectin and mebendazole to treat cancer patients has been conducted.

It reveals that after just 6 months of treatment, 84.4% of cancer patients reported clinical benefit; nearly reported no evidence of disease or tumour regression, while over a third reported disease stabilisation.

“This means more than four out of five patients reported either improvement or stabilisation of their cancer,” Nicholas Hulscher writes. [Read More]